The Digital Out-of-Home (DOOH) advertising market within clinical settings has revealed a significant pricing inefficiency that could reshape the industry. Screen owners have created an intensely engaging advertising environment tailored for a captive audience—patients focused on specific medical issues, often just after a critical clinical conversation. However, these screens command a cost per thousand (CPM) similar to traditional channels that lack the guarantee of human presence in the room.
This pricing anomaly has implications that extend far beyond mere inefficiency. It stems from a fundamental failure to accurately assess the value of this unique advertising channel, which continues to persist not due to a lack of worth in the inventory but because the supporting infrastructure to validate its effectiveness has not kept pace.
As this gap begins to close, the potential revaluation of the entire DOOH sector looms. Clinical screens offer a unique proposition wherein patients, engaged and attentive, are unlikely to encounter distractions, making them ideal for targeted advertisements. For instance, a patient attending a cardiology follow-up may spend approximately twenty minutes in a focused state, thinking solely about their health issue and treatment options.
In stark contrast, other advertising platforms consistently miss their target audiences. Reports indicate that almost 29% of television advertisements are aired to empty rooms, while around 40% of digital budgets fail to reach the intended audience. These figures, widely accepted within the industry, highlight the substantial waste that companies are content to absorb as part of their media strategies.
Research shows that advertising at the point of care yields notably better outcomes. Patients exposed to on-site advertisements are significantly more inclined to engage with their healthcare providers regarding treatments than those who encounter the same marketing via television. Specific statistics reveal that 84% of patients noticing in-office advertisements are encouraged to discuss the treatment with their physicians during the consultation, with 68% expressing a desire for more information on a particular medication.
This level of engagement points to a high-value marketing channel currently underpriced compared to its potential, as the pharmaceutical industry expands its investments into clinical settings driven by compelling evidence of effectiveness.
Recent figures indicate that revenue from point-of-care advertising has surpassed the billion-dollar mark in 2024, reflecting over a 170% increase from 2019 to 2023. This growth confirms the pharmaceutical industry’s evolving approach to marketing, as brands recognize the unparalleled advantages of reaching patients directly within clinical environments.
However, pharmaceutical marketing teams are now applying rigorous performance metrics to their clinical selections, demanding precise audience targeting and verifiable impressions that were once considered differentiators. In today’s landscape, the expectation has shifted, with marketers seeking to ensure campaigns reach patients at the precise intersection of health conditions and clinical context, backed by thorough post-campaign reporting.
The challenge lies in establishing robust proof of impact, as current clinical advertising efforts struggle to demonstrate beyond theoretical value. Networks that can successfully bridge this proof gap will redefine market expectations for DOOH advertising, moving it from a perceived basic service to a high-performing channel with substantial growth potential.
Addressing the proof issue will not simply tweak CPM rates. Rather, it stands to redefine how the category is valued altogether. When patients receive relevant communications aligned with their health conditions, they arrive at consultations better informed and more likely to discuss the details with their healthcare providers. Should pharmaceutical brands be able to confirm that delivered impressions accurately match patient-specific criteria, the narrative will shift—from mere context-based spending to a performance-driven model justifying significant budget increases.
Some leading pharmaceutical marketers are already strategizing campaigns that leverage clinical encounters as foundational touchpoints while integrating other advertising channels for amplification. The networks that can align their offerings with these expectations will not only capture a share of an expanding budget but also set new value benchmarks for the DOOH clinical space.
Thus, the challenge of proximity has morphed into one demanding both proximity and proof. With the right technological advancements in place, the sector is poised to undergo a much-needed recalibration, propelling the value of clinical DOOH advertising to new heights.
Photo: Dilok Klaisataporn, Getty Images
